Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 654

2.

Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) distribution in normal and pathological human bone.

Bord S, Horner A, Beeton CA, Hembry RM, Compston JE.

Bone. 1999 Mar;24(3):229-35.

PMID:
10071915
3.

Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.

Vaillant C, Didier-Bazès M, Hutter A, Belin MF, Thomasset N.

J Neurosci. 1999 Jun 15;19(12):4994-5004.

4.

Matrix metalloproteinases: role in skeletal development and growth plate disorders.

Malemud CJ.

Front Biosci. 2006 May 1;11:1702-15. Review.

PMID:
16368549
5.

Expression patterns of matrix metalloproteinases and vascular endothelial growth factor during epiphyseal ossification.

Alvarez J, Costales L, Serra R, Balbín M, López JM.

J Bone Miner Res. 2005 Jun;20(6):1011-21. Epub 2005 Feb 7.

6.

Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium.

Freitas S, Meduri G, Le Nestour E, Bausero P, Perrot-Applanat M.

Biol Reprod. 1999 Oct;61(4):1070-82.

PMID:
10491646
7.

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints.

Takei I, Takagi M, Santavirta S, Ida H, Hamasaki M, Ishii M, Fukushima S, Ogino T, Konttinen YT.

J Biomed Mater Res. 1999 Jun 5;45(3):175-83.

PMID:
10397973
9.
10.

Matrix metalloproteinases and their tissue inhibitors in the developing neonatal mouse uterus.

Hu J, Zhang X, Nothnick WB, Spencer TE.

Biol Reprod. 2004 Nov;71(5):1598-604. Epub 2004 Jul 7.

PMID:
15240428
11.

Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.

Zhang X, Sakamoto T, Hata Y, Kubota T, Hisatomi T, Murata T, Ishibashi T, Inomata H.

Exp Eye Res. 2002 May;74(5):577-84.

PMID:
12076079
12.

Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes.

Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R.

J Pathol. 2004 Mar;202(3):367-74.

PMID:
14991903
13.
14.

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R.

Eur J Cancer. 2003 Sep;39(13):1948-56.

PMID:
12932675
15.

Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.

Papakonstantinou E, Dionyssopoulos A, Aletras AJ, Pesintzaki C, Minas A, Karakiulakis G.

J Am Acad Dermatol. 2004 Oct;51(4):526-33.

PMID:
15389186
16.

Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs).

Lafleur MA, Handsley MM, Knäuper V, Murphy G, Edwards DR.

J Cell Sci. 2002 Sep 1;115(Pt 17):3427-38.

17.

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human fetal testis and ovary.

Robinson LL, Sznajder NA, Riley SC, Anderson RA.

Mol Hum Reprod. 2001 Jul;7(7):641-8.

PMID:
11420387
18.
19.

Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells.

Uchida M, Shima M, Shimoaka T, Fujieda A, Obara K, Suzuki H, Nagai Y, Ikeda T, Yamato H, Kawaguchi H.

J Cell Physiol. 2000 Nov;185(2):207-14.

PMID:
11025442

Supplemental Content

Support Center